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ABSTRACT
The Ul snRNP-specific protein C contains an
N-terminal zinc finger-ike CH motif which is required
for the binding of the U1C protein to the Ul snRNP
particle. Recently a similar motif was reported to be
essential for in vivo homodimerization of the yeast
splicing factor PRP9. In the present study we demon-
strate that the human UIC protein is able to form
homodimers as well. UlC homodimers are found when
(i) the human U1C protein is expressed in Escherichia
coil, (ii) immunoprecipitations with anti-UI C anti-
bodies are performed on in vitro translated Ul C, and
when (iii) the yeast two hybrid system is used.
Analyses of mutant UlC proteins in an in vitro
dimerization assay and the yeast two hybrid system
revealed that amino acids within the CH motif, i.e.
between positions 22 and 30, are required for homo-
dimerization.
INTRODUCTION
During the process ofpre-mRNA splicing, the U 1 snRNP particle
binds to the 5' splice site of the pre-mRNA resulting in the
formation of a commitment complex (1). In addition to the
so-called common or Sm proteins (2) which are also present in the
U2, U4 and U5 snRNPs, U1 snRNP contains three specific
proteins denoted U1-70K, U1A and U1C (2,3). For its activity in
splicing both the Ul RNA and protein, components are known to
be needed but the precise function in the splicing process of the
latter is only poorly understood (1-5). Recently it was shown by
in vitro studies that the U1-70K protein plays an essential role in
splicing, a role in which the phosphorylation state of.the protein
appears to be crucial (6).
With regard to the UIC protein, Heinrichs and co-workers (7)
performed a functional study in which the pre-mRNA binding
capacity of Ul snRNP particles containing or lacking the UIC
protein was compared in an in vitro assay. U1 snRNPs lacking the
U1C protein bound to the pre-mRNA 5' splice site with only 40%
efficiency as compared with complete Ul snRNPs. Binding
efficiency could be restored to wild-type levels by adding purified
HeLa U1C protein. These results suggested that the U1C protein
is involved in the binding of the Ul snRNP particle to the 5' splice
site.
In contrast with the U1-70K and UlA protein, the U1C protein
does not contain an RNP-80 or RNA recognition motif (8).
Lacking such a motif, the U1C protein can only bind to the Ul
snRNP particle when the U1-70K and common proteins are
already associated with the Ul RNA (9). The N-terminal region of
U1C, containing a zinc finger-like sequence which resembles the
CC-HH zinc fingers of the TFIIIa type, is required and sufficient
for this interaction (10). Similar CH motifs have been observed
in the yeast splicing proteins PRP6, PRP9 and PRP1 1 (11,12).
Neither one of the proteins U1C, PRP6, PRP9 or PRP1 1,
however, has actually been shown to bind zinc. Recently, Legrain
and co-workers (13) demonstrated in the yeast two hybrid system
that the two CH motifs in the PRP9 protein are required for the
formation of PRP9 homodimers.
In the present study we show that the humanU1C protein is able
to form homodimers as well. U1C dimers were detected in
preparations ofhuman U 1C protein expressed in Escherichia coli
and dimerization could be induced with in vitro translated U1C.
In both an in vitro dimerization assay and the yeast two hybrid
system it could be demonstrated that amino acid residues between
positions 22 and 30 are required for dimerization.
MATERIALS AND METHODS
Expression and purification of (his)6-tagged human
U1C protein in E.coli
Using site directed mutagenesis an NdeI site was introduced at the
translational start codon of the human U1C cDNA, which was
cloned into pGEM-3Zf(+). By PCR the translational stop codon
of the (NdeI)U1C cDNA was replaced by the codons of six
histidine residues, followed by a stop codon and a BamHI site.
Subsequently the UlC(his)6 cDNA was recloned as an NdeI-
BamHI fragment into the expression vector pET-3b (14) and with
this construct E.coli strain BL21(DE3)pLysS (15) was trans-
formed. The human UlC(his)6 protein was overexpressed (16),
followed by freeze-thawing and sonication of the cells in 10 ml
PBS with 0.5 mM PMSF, 10 mM MgCl2 and 0.5 mg DNAse I.
After centrifugation all U I C(his)6 was present in the non-soluble
fraction which could be dissolved in 8 M urea. In the text the
solubilized UlC(his)6 fraction is referred to as UIC(his)6 bacterial
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extract. A control extract was prepared from BL21(DE3)pLysS
transformed with pET-3b lacking the U1C cDNA.
The U 1C(his)6 protein was purified from the bacterial extract
following the procedures described by Janknecht et al. (17) and
Schmitt et al. (18). UIC(his)6 bacterial extract was incubated
batchwise at 20°C with Ni-NTA-agarose beads (Qiagen) and
IPP1Io (10 mrM Tris-HCl pH 8.0; 100mM NaCl; 0.05% NP-40).
Proteins bound to the Ni-groups were eluted batchwise by
incubating the beads two times during 5 min with elution buffer
D [ 10mM HEPES pH 7.9; 5 mM MgCl2; 0.1 mM EDTA; 50mM
NaCl; 17% glycerol (v/v); 1 mM DTE; 1 mM PMSF; 10 mM
NaF] containing increasing concentrations of imidazole: 40 mM,
60 mM, 200 mM, 500 mM. When the purification was performed
under non-reducing conditions, DTE was omitted from the elution
buffer.
Site directed mutagenesis
Single-stranded DNA of the U1C cDNA cloned into
pGEM-3Zf(+) was produced with the helper phage M13K07. Point
mutations were introduced into the cDNA using the oligo-directed
mutagenesis system kit from Amersham and checked by
sequencing.
In vitro transcription and translation
To produce T7-U1C mRNA for translation, 1 ,ug of linearized
template was transcribed in essentially the same manner as
described by Scherly et al. (19). The cDNA encoding U1C was
recloned in pGEM-3Zf(+)(Promega) lacking a functional BamHI
site, as described previously (10). To produce 35S-labeled U1C
protein or derivatives thereof, 200 ng (2 g1) of the corresponding
T7-mRNA were incubated with wheat germ extract (Amersham)
and 35S-methionine (Amersham) in essentially the same manner
as described by Scherly et al. (19).
Truncated C proteins
To produce templates for the truncated human U1C proteins
containing amino acids 23-159 and 30-159, the codons for residues
21/22 or 28/29 in the U1C cDNA were replaced by a BamfHI site
(contains codons for Gly and Ser) using the site directed mutagenesis
technique. The U1C sequences coding for residues 23-159 and
30-159 respectively, were subcloned as BamHI-HindIll fragments
directly behind the start codon of the mutant UlA (2/3) construct,
in which codons for residues 2 and 3 were replaced by a BamHI site
(20). Except for the U1A start codon the new U1C constructs do not
contain any other U 1A codons.
In vitro U1C dimerization assay
UIC(his)6 containing bacterial extract (15 ,l) was incubated for
1 h at 200C with 20 ,l Ni-NTA-agarose (50% slurry) and 30 p1
IPP150. The beads were washed three times with 0.5 ml IPP150,
resuspended in 20 ul IPP150 and incubated for 1 h at 20°C with
2 p1 in vitro translated 35S-labeled U1C protein, or mutants
thereof. Non-bound protein was removed by extensive washing
with IPP150. All 35S-labeled U1C associated with UIC(his)6
protein bound to Ni-groups was eluted by incubating the beads
with 20 ,l elution buffer D containing 200 mM imidazole, but
lacking DTE. The ULC(his)6 was present in excess over the
35S-labeled U1C protein, because when more 35S-labeled U1C
was added to the assay also more 35S-labeled U1C could be
precipitated (data not shown). The elution fractions were separated
on an SDS-polyacrylamide gel. When separation was performed
under non-reducing conditions the f-mercaptoethanol (5%) was
omitted from the sample buffer.
Immunodetection of Ul snRNP proteins on Western
blot
Ul snRNP proteins transferred to nitrocellulose were detected by
immunostaining with monoclonal (nmouse) and monospecific
(rabbit) antibodies specifically directed against Ul snRNP proteins,
and with phosphatase-conjugated second antibodies as described
by Lehmeier et aL (21). The monoclonal mouse antibodies used
were directed against the U1-70K (HI1) (22), U1A (9A9) (23),
B/B' (KSm5) and Dl (KSm2) (24) proteins. Monospecific rabbit
antibodies specifically raised against a peptide or recombinant
fragment of the respective antigen, were used to detect the U1C,
D3, D2, F and G (25) protein. Anti-(his)6 antibodies were raised
by immunizing a rabbit with (his)6 coupled to BSA (Euro-
Diagnostica B.V., Apeldoom, The Netherlands). The
anti-(his)6-tag antibodies do recognize U lC(his)6 protein but not
U1C protein lacking the (his)6-tag.
Detection of U1C homodimers using the yeast two hybrid
system
Cloning ofthe UlCfision proteins. A cloned humanUIC cDNA
(26) was used as a template for PCR amplification with different
primers. The resulting DNA fragments encode the wild-typeU IC
protein or various N-terminal deletion mutants [corresponding to
UIC(63-159), UIC(23-159) and UIC(30-159); see Fig. 4A].
These DNAs were cloned in the pAS2 plasmid, allowing synthesis
of corresponding fusion proteins with the Gal4 DNA binding
domain (Gal4BD). The wild-type amplified DNA fragment was
also cloned in the pACTII plasmid for production of fusion protein
with the Gal4 activator domain (Gal4AD; 27,28). Sequences of
PCR amplified fragments were verified.
Yeast manipulations. Yeast cells were grown and transformed
according to standard procedures. The Y526 yeast strain (MATa,
his3- ade2, lys2- trpl- leu2- canR, gal4- gal8O-
URA::GALJ-lacZ) was transformed with the two-plasmids and
transformants were selected on minimal medium lacking leucine
and tryptophan and assayed for 0-galactosidase activity using a
filter assay with X-gal. Several colonies were streaked and cells were
grown in liquid cultures to perform quantitative P-galactosidase
assays (13).
RESULTS
Expression and functionality of recombinant UlC(his)6
protein
To investigate whether U1C is able to form homodimers, the
human U1C protein with a C-terminal tag of six histidine residues,
was expressed in E.coli. The expressed UIC(his)6 protein was
detected on a Coommassie Brilliant Blue stained SDS-polyacry-
lamide gel as a prominent 21 kD band, which was not present in
a control extract of bacteria lacking U IC(his)6. This 21 kD band
corresponds with the expected mobility of the U1C protein from
HeLa cells (26) and is immunologically recognized on a Western
blot by anti-UlC monospecific antibodies directed to the CH
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motif of the protein and by anti-(his)6 polyclonal antibodies (data
not shown). Both antibodies did not crossreact with bacterial
proteins. Interestingly, a band of -42 kD was also detected with
both antibodies. The characterization of this band will be discussed
below.
The UIC(his)6 protein was purified from the extract with
Ni-NTA-agarose. Proteins bound to the Ni-NTA-groups were
specifically eluted with increasing imidazole concentrations. The
UIC(his)6 protein was eluted most efficiently at a concentration of
200 mM imidazole (data not shown). The purified UIC(his)6
protein seems to be functional since it is capable of competing
with in vitro translated 35S-labeled U1C protein for binding to Ul
snRNPs (data not shown) in an S100 reconstitution assay as
described previously (10).
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Recombinant human U1C prtein is able to form
homodimers
Based on the immunostaining ofa42 kD band as described above,
we hypothesized that the 42 kD complex might represent a
UIC(his)6 homodimer. To detect the putative UIC(his)6 dimer
band on a Coomassie stained gel as well, the purification with
Ni-NTA-agarose was repeated under non-reducing conditions,
i.e. without DTE in the bacterial extract and elution buffers.
Subsequently, samples of the elution fractions were separated
under non-reducing conditions, i.e. 3-mercaptoethanol was
omitted from the sample buffer, on an SDS-polyacrylamide gel
(Fig. lA). Following this procedure -90% of the UlC(his)6 in the
bacterial extract was retained on the Ni-NTA-agarose beads
(compare lanes 2 and 3). Most of the eluted UIC(his)6 is present
in the 200mM imidazole elution fraction (lane 6) but at 500mM
imidazole a considerable amount ofUlC(his)6 was eluted as well
(lane 7). The bands which migrate at -12 and 16 kD most likely
represent distinct U1C degradation products. Figure 1A (lanes
5-7) demonstrates that under non-reducing conditions the putative
UlC(his)6 homodimer of 42 kD indeed can be detected on a
Coomassie stained gel. The finding that this band is only present
in the imidazole eluted protein preparation under non-reducing
conditions suggests that the 42 kD band corresponds to a complex
of proteins held together by one or more disulfide bridges.
To provide more evidence for the presence of the UlC(his)6
protein in the 42 kD complex, UlC(his)6 bacterial extract was
separated on an SDS-polyacrylamide gel under non-reducing
conditions. As a control, bacterial extract lacking UIC(his)6 was
separated on the same gel. With reference to the markers a gel
piece from the lanes of both extracts was cut out of the gel at the
position of the 42 kD band and extracted with standard reducing
SDS-sample buffer. Both samples were separated on an SDS-
polyacrylamide gel and Western blotted. Figure lB shows the
Western blot immunostained with monospecific antibodies
directed to the U1C protein. With antibodies directed to the
(his)6-tag similar results were obtained (not shown). In the control
lane (lane 1) no proteins were detected with anti-UlC antibodies.
The 42 kD complex from the UlC(his)6 bacterial extract,
however, could partly be reduced to UIC(his)6 monomers,
migrating at 21 kD (Fig. lB, lane 2). A similar result was obtained
when purified, non-reduced U1C(his)6 (200 mM imidazole
elution fraction; Fig. IA, lane 6) was pre-incubated with 25 mM
DTE and separated by SDS-PAGE in the presence of DTE (data
not shown). These results indicate that the UlC(his)6 protein
expressed in E.coli indeed is able to form homodimers, which
Figure 1. Detection of U C(his)6 homodimers. (A) Purification under
non-reducing conditions of recombinant U 1 C(his)6. Coomassie Brilliant Blue
stained 10% SDS-polyacrylamide gel: lane 1: protein molecular weight
markers; lane 2: 1 gl UIC(his)6 bacterial extract, of which 2.5 ml was used for
purification of UlC(his)6; lane 3: 3 g1 ofthe supernatantcontaining the proteins
which did not bind to the Ni-NTA-agarose. The U IC(his)6 protein was eluted
batchwise with increasing concentration of imidazole. Of the elution fractions
(2 ml in volume each) 10 gl was separated on gel; lane 4: 40 mM imidazole
fraction; lane 5: 60 mM imidazole fraction; lane 6: 200mM imidazole fraction;
lane 7: 500 mM imidazole fraction; lane 8: 1% of the proteins which were still
associated with the Ni-NTA-agarose beads after the elution procedure,
dissolved in SDS-sample buffer. (B) Immunostaining of Western blot with the
excised, non-reduced 42 kD band (band I) after separation under reducing
conditions. UIC(his)6 containing bacterial extract (20 ,u) and bacterial extract
lacking UIC(his)6 (20 1l) were separated by non-reducing SDS-PAGE. From
the lanes of both extracts a gel piece was excised at the position of42 kD (band
I) which was crushed and analyzed on a reducing 15% SDS-polyacrylamide
gel. Proteins were transferred to nitrocellulose and immunostained with
monospecific anti-UIC antibodies. Lane 1: proteins from bacterial extract
lacking UlC(his)6 at a position that corresponds with band I [I(be)]; lane 2:
band I from bacterial extract containing UIC(his)6 [I(be+C)].
might be stabilized by one ore more disulfide bridges. Apparently
not all of the UlC(his)6 dimers were reduced in the experiment
of Figure lB since the 42 kD band still could be detected. This
may be due to the relatively high concentration of the recombi-
nant U1C protein or limited accessibility of a disulfide bridge.
In vitro translated U1C forms homodimers as well
In order to test whether U1C homodimers also can be detected
when the protein is synthesized in vitro we immunoprecipitated
35S-labeled U1C translated in wheat germ extract using polyclonal
anti-UlC antibodies. Figure 2, lane 3 indicates that indeed a
complex at the dimer position is precipitated. As a control the
Ul C dimer obtained in our in vitro dimerization assay (see below)
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Figure 2. Immunoprecipitation of in vitro translated U1C. In vitro translated UIC
(2 gl) was incubated for 90 min at 20°C with polyclonal anti-UIC antibodies
coupled to protein-A agarose beads (Biozym) in a final volume of 40 ul IPP150.
The beads were washed three times with 1PPI50 and resuspended in non-reducing
SDS sample buffer. The supematants were separated on a 10% SDS-polyacry-
lamide gel. Lane 1: Protein molecular weight markers; lane 2: 10% of the input
of in vitro translated 35S-labeled UIC; lane 3: immunoprecipitation of 2 g1 in
vitro translated UIC via polyclonal anti-UIC antibodies; lane 4: control lane
with the dimer obtained from the in vitro dimerization assay (see Fig. 3).
was used (Fig. 2, lane 4). The dimer from the in vitro ULC
translation migrates somewhat faster than the dimer generated in
the dimerization assay (Fig. 2, compare lanes 3 and 4) because the
in vitro translated protein lacks a (his)6-tag. No dimers were
observed when the U1C translation mixture was separated by
non-reducing SDS-PAGE (Fig. 2, lane 2).
non
B 10%reducing reducing
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The dimerization assay
An in vitro dimerization assay was developed in which the
dimerization between UlC(his)6 expressed in E.coli and in vitro
translated 35S-labeled U1C could be analyzed in more detail (Fig.
3A).
In this assay, UIC(his)6 from a bacterial extract was coupled to
Ni-NTA-agarose beads. All non-bound proteins were removed
by extensive washing of the beads. Based on the results obtained
by SDS-PAGE analyses shown above we can assume that
UIC(his)6 is present on the Ni-beads as a mixture of monomers
and dimers. The UIC(his)6-Ni-beads were then incubated with
in vitro translated 35S-labeled human UlC protein lacking a
(his)6-tag. Following several wash steps the bound UlC(his)6 and
the 35S-labeled UlC associated with it, were specifically eluted
by 200mM imidazole. As a negative control the 35S-labeled UlC
was added to Ni-NTA-agarose beads pre-incubated with bacter-
ial extract lacking UlC(his)6.
One sample of each elution fraction was analyzed on a standard
reducing SDS-polyacrylamide gel, another sample on a
non-reducing gel, i.e. in the absence of f3-mercaptoethanol.
Figure 3B, lane 2 demonstrates that a 35S-labeled protein(com-
plex) of-41 kD is eluted in the absence of a reducing agent. Since
the 41 kD band was never observed in the control assays (lanes
3 and 5) it is most likely to conclude that the 41 kD complex
corresponds to a dimer formed by UIC(his)6 and 35S-labeled
U1C [this dimer thus migrates somewhat faster than the 42 kD
UIC(his)6 homodimer]. As expected the 35S-labeled 41 kD
complex is destabilized under reducing SDS-PAGE conditions
U1-C 4mm_ u_ - 20.5
1 2 3 4 5
Figure 3. The dimerization assay. (A) Scheme of the in vitro U IC dimerization
assay. U 1 C(his)6 from bacterial extract was coupled to Ni-NTA-agarose beads.
The UIC(his)6-beads were incubated with in vitro translated 35S-labeled U1C
protein or mutants thereof and precipitated 35S-labeled protein was eluted from
the beads with 200 mM imidazole containing elution buffers. The eluted
35S-labeled protein was visualized by SDS-PAGE followed by autoradiography.
(B) Dimerization of 35S-labeled U IC and recombinant UI C(his)6. Lane 1: 0%
of the input of in vitro translated 35S-labeled U1C protein; lanes 2 and 3:
non-reductive separation of 35S-labeled U IC eluted from beads containing or
lacking UIC(his)6, respectively; lanes 4 and 5: as lanes 2 and 3, but analyzed by
SDS-PAGE with sample buffer containing 5% P-mercaptoethanol.
and only U1C monomers can be detected (lane 4). The eluted
35S-labeled U1C monomers seen in lanes 2 and 4 are probably
generated by background binding of 35S-labeled U1C to
Ni-agarose associated bacterial proteins (see background lanes 3
and 5) and by destabilization of eluted dimers.
Amino acids between positions 22 and 30 are required
for homodimerization
To determine which part of the U1C protein is involved in dimer
formation 35S-labeled U1C mutant proteins (Fig. 4A) were tested
in the in vitro dimerization assay. The mutant UIC(I-60) is
A
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Figure 4. In vitro dimerization of 35S-labeled U IC or mutants thereof and
UlC(his)6 immobilized on Ni-NTA-agarose. As a control the 35S-labeled
proteins were tested with Ni-beads which were preincubated with bacterial
extract lacking U I C(his)6. (A) Schematic representation of the mutant proteins
derived from the wild-type human UIC protein. The amino acid numbers are
indicated. The shaded box represents the proline and methionine rich
C-terminal domain, starting at residue 61. Dark-grey boxes indicate the position
at which an amino acid is substituted by another residue [UIC mutants (s25):
substitution of cysteine by serine; (s24) and (s30): substitution of histidine by
glutamine; (s21/22): substitution of arginine/lysine by glycine/serine].
(B) 200 mM imidazole elution fractions of 35S-labeled UIC (wild-type) and
UIC mutants tested in the dimerization assay and separated by non-reducing
SDS-PAGE. Lanes 1: 10% of the 2 ,ul input of in vitro translated 35S-labeled
UIC protein (wild-type or mutant); lanes 2 and 3: 35S-labeled UIC (wild-type
or mutant) eluted from beads containing (+C) or lacking U I C(his)6 (-C)
respectively. The assay was performned with the mutant proteins UlC(1-60),
UlC(23-159), UIC(30-159), UIC(s21/22), UIC(s24), UIC(s25) and UIC(s30)
respectively.
known to bind to U 1 snRNP with comparable efficiency as the
wild-type protein (9). The U IC substitution mutants (s24) and
(s30), in which a histidine residue is substituted by a glutamine,
were previously reported to have lost their ability to bind to U 1
snRNP. In contrast, substitution of the Cys-25 by Ser-25 (mutant
s25) did not affect binding to U1 snRNP (10). Additionally, a
double point mutant was made in which the codons for the
residues Arg-2I/Lys-22 were substituted by a BamHI site, which
codes for glycine/serine. This mutant UlC(s21/22) cannot bind
to U 1 snRNP (data not shown). Following the incubation of an
35S-labeled mutant U IC protein in the dimerization assay the 200
mM imidazole elution fraction was analyzed on an SDS-poly-
acrylamide gel under non-reducing conditions. Wild-type U 1 C
protein was included as a positive control (Fig. 4B).
The U1C(1-60) protein seems to dimerize with UlC(his)6
almost as efficient as the wild-type protein. The N-terminal
domain, containing the zinc finger-like region thus appears to be
sufficient for in vitro dimerization. Further analyses of N-terminal
deletion mutants show that the first 22 amino acids, which
encompass the two conserved cysteines of the zinc finger-like
region, are not essential for dimerization. The mutant protein
UlC(23-159) still is able to dimerize with UlC(his)6 whereas
U 1 C(30-159) has completely lost its ability to interact with
UlC(his)6 [Fig. 4B, lanes 2 of (23-159) and (30-159)1. All the
mutations which previously were shown to abolish binding to U 1
snRNP hardly or only moderately interfered with dimerization in
this assay [Fig. 4B, lanes 2 of (s21/22), (s24), (s30)]. When
Cys-25 is substituted, no stable dimers can be detected after
SDS-PAGE (Fig. 4B, lane 2 of s25), indicating that Cys-25 is
most likely the residue responsible for disulfide bridge formation
between two U 1C proteins. However, as for all dimerizing U 1C
derivates, incubation of mutant s25 leads to a specific monomeric
signal (Fig. 4B, lanes 2). These results suggest that s25 is able to
form homodimers purely as a result of non-covalent interactions
which are disrupted during SDS-PAGE.
The N-terminal deletion mutant U I C(23-159) for some reason
gives a higher monomer background in the dimerization assay. At
the moment we have no explanation for this phenomenon.
Similar results were obtained when in vitro translated
35S-labeled mutant U1C proteins were immunoprecipitated via
polyclonal anti-U 1 C antibodies, as in the experiment of Figure 2
(data not shown).
U1C homodimers are detected in the yeast two hybrid
assay
To verify the results of our in vitro assays, we used the two hybrid
assay in yeast which allows the detection of protein-protein
interactions in vivo (29). When the two U IC wild-type fusion
proteins were expressed in yeast, 3-galactosidase activity was
detected using a qualitative X-gal conversion assay (data not
shown). This was specific since the production of any of the two
fusion proteins in combination with an irrelevant protein did not
induce P3-galactosidase synthesis. However, transformants grew
slowly and, when primary transformants were streaked on plates,
fast growing variants were often recovered which were systemati-
cally negative in an X-gal conversion assay.
To analyze the formation of U 1 C protein homodimers in more
detail, several versions of the U 1C protein fused to the Gal4 DNA
binding domain were assayed in combination with the wild-type
U 1C partner fused to the Gal4 activation domain. In Figure 5 it
is shown that dimers are formed between wild-type and
UlC(23-159) proteins and resulting ,-galactosidase activities are
comparable or even higher than those detected for the wild-type
homodimer. The various clones exhibited different activities,
._t4"
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Figure 5. Analysis of UIC dimers in the yeast two hybrid assay. Fusion proteins
expressed by the cells are indicated below the histograms (Gal4AD fusion
protein/Gal4BD fusion protein). Five independent transformants were streaked
for each experiment. PRP21 is a yeast splicing factor (28). Assays were done in
duplicate for each transformant and the values were within a 0% variation range.
probably reflecting a variable amount of negative variants arising
during the liquid culture. When the wild-type UIC fused to the
GALA activation domain was replaced by an irrelevant protein such
as PRP21, no ,-galactosidase activity was observed indicating that
the activity measured for the combination of the wild-type UIC
and the UlC(23-159) proteins very likely reflects the formation
of a dimer. Similarly, the co-expression of the wild-type UIC
protein in combination with UIC(30-159), UlC(63-159) or an
irrelevant protein did not lead to any detectable P-galactosidase
activity. A number ofU 1C point mutants (s6, s9, s24, s25 and s30)
were tested in the yeast two hybrid assay as well. These mutants
also showed dimer formation in vivo (data not shown). Our results
suggest that in the yeast two hybrid system non-covalent
interactions are sufficient for U1C dimerization. We conclude that
in the two hybrid assay U IC homodimers are detected and that
their assembly points to a functional region between the amino
acid residues 22 and 30, which is in agreement with the results
obtained with our dimerization assay.
Are U1C homodimers present in HeLa Ul snRNPs?
Assuming that dimerization of the human U1C protein has
functional implications, it would be interesting to investigate
whether UlC dimers are present in Ul snRNP particles as well.
For the detection of UIC homodimers in U1 snRNPs, U1
particles were purified from HeLa cells as described by Bach et
al. (30) and its protein components were separated on a reducing
and a non-reducing SDS-polyacrylamide gel followed by
Western blotting (Fig. 6). Individual Ul snRNP proteins were
visualized on the blot by immunostaining with monoclonal or
monospecific antibodies specifically raised against particular U 1
snRNP proteins, except for Sm-E, as described previously (9).
Under reducing conditions the U1C protein was detected as a
monomer migrating at a position of 21 kD. However, under
non-reducing conditions not only U1C monomers were detected
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
Ul snRNPs from HeLa cells
Figure 6. Detection ofU1C dimers in Ul snRNPs by immunostaining. Native
U 1 snRNPs were isolated from HeLa cells by immunoaffinity chromatography
followed by Mono Q chromatography as described by Bach et al. (30)
(generous gift of C. Will and R. Luhrmann, Marburg). Ul snRNPs (-50 jig;
protein weight) were separated on a 10% SDS/high TEMED-polyacrylamide
gel under reducing or non-reducing conditions and transferred to nitrocellulose.
The nitrocellulose lanes were cut into strips and each strip was immunostained
with a monoclonal or monospecific antibody directed to the U I snRNP proteins
U1-70K (lanes 1), U1A (lanes 2), Sm-B/B' (lanes 3), U1C (lanes 4), Sm-D3
(lanes 5), Sm-D2 (lanes 6), Sm-DI (lanes 7), Sm-F (lanes 8) and Sm-G (lanes
9) respectively. Left panel: Ul snRNP proteins separated under reducing
conditions; right panel: Ul snRNP proteins separated under non-reducing
conditions. The arrowhead indicates the position of the U1C homodimer.
with monospecific anti-UlC antibodies, but also a band of -42
kD which corresponds to the expected molecular weight of UIC
homodimers (Fig. 6, lane 4). Since none of the other antibodies
stained a protein(complex) at the same position, these results
suggest that UIC homodimers indeed are present in HeLa Ul
snRNPs. Because the experiment was performed under condi-
tions which are not favourable to interparticle interactions (22)
the possibility of such interactions involving the U1C protein
seems unlikely. We were not able to detect dimers in U 1 snRNP
particles purified from HeLa S100 extract using sucrose gradient
centrifugation (data not shown). We do not know whether U1C
dimers are not present in this Ul snRNP population or that dimers
have already been reduced to monomers due to the isolation and
separation procedures.
DISCUSSION
Our results demonstrate that the human U1 snRNP-specific protein
C is able to form homodimers. The finding that the residues
between positions 22 and 30 within the CH-motif are necessary for
dimerization, as shown in an in vitro dimerization assay and in the
yeast two hybrid system, is in principle in agreement with the
reported involvement of the two zinc finger-like motifs in the
homodimerization of the yeast splicing factor PRP9 (13). Legrain
and co-workers observed in the yeast two hybrid system that
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homodimerization of PRP9, mutated in the conserved cysteine
and histidine residues of the CH motif, was reduced with at least
one order of magnitude. Our mutational analysis of the U1C zinc
finger-like region in both our dimerization assay and the yeast two
hybrid system showed that the amino acids between positions 22
and 30 are important for homodimerization. The conserved
cysteines at positions 6 and 9 seem less important since deletion
of the N-terminal 22 amino acids did not affect dimerization in the
in vitro dimerization assay (Fig. 4) and the yeast two hybrid
system (Fig. 5). Further analyses of point mutants within the
region between amino acids 22 and 30 of the U1C protein showed
that the residues which previously had been indicated to be
important for binding of the Ul snRNP particle (10), seem less
important for homodimerization. Substitution of the conserved
histidine residues in the CH motif (amino acids 24 and 30) hardly
or only moderately affected the dimerization efficiency in our
dimerization assay (Fig. 4B). Based on these observations and the
finding that dimers are stable under non-reducing SDS-PAGE
conditions, we conclude that in vitro residue Cys-25 is likely to
be involved in the formation of a disulfide bridge between two
U1C molecules. This conclusion is in concert with data reported
by Benezra (31) who showed that E2A proteins, a subfamily of
the basic helix-loop-helix family of DNA-binding proteins, form
homodimers that are linked via a disulfide bond. However, the
appearance of relatively high monomer signals in our dimeriz-
ation assay (Fig. 4B) do indicate that non-covalent interactions
are involved in dimer formation as well.
We were also able to show the formation of U1C dimers with
in vitro translated U1C. When a U1C translation mixture was
separated by non-reducing SDS-PAGE no dimers were observed
(Fig. 2, lane 2). However, U1C dimers could be detected after
immunoprecipitation with anti-UIC antibodies (Fig. 2, lane 3).
Since formation of dimers most likely depends on the concentra-
tion of the monomer protein, dimerization might be facilitated by
binding of U1C to the bivalent antibodies. Alternatively, the
binding of the antibodies could stimulate the U1C protein to adopt
its native structure. Such antibody assisted protein folding has been
demonstrated by Carlson and Yarmush for the ribonuclease A
S-protein (32). A third possibility is that the cell-free translation
system contains a component that prevents dimer formation, as
indeed has been suggested by Benezra (31). By immunopreci-
pitation of U1C this component might be separated efficiently
from the U1C protein.
Our data indicate that the U1C protein can form homodimers
in vivo as well. This was shown in the yeast two hybrid assay (Fig.
5). Using this system the importance of the amino acids 23-29 of
the U1C protein for dimer formation was corroborated. Indeed,
the absolute values of ,B-galactosidase activity are low compared
with those found for other homodimers detected with the yeast
two hybrid assay, such as PRP9 (40 units, ref. 28). Nevertheless,
the positive results with the U1C protein were reproducibly
found. It should be stressed that in the case of homodimerization,
an inhibition of productive interactions may occur due to the
formation of true homodimers between identical fusion proteins.
The exact nature of the link between the two U 1C monomers in
vivo is not precisely known. In our in vitro experiments the
formation of a disulfide bridge in addition to non-covalent
interactions is necessary for the detection of U1C dimers after
SDS-PAGE, as has been discussed above. In the yeast two hybrid
system probably only non-covalent interactions between the two
monomers exist as has been suggested by the positive results
obtained with the UIC point mutants. But also in vivo such
non-covalent interactions are primarily mediated by amino acid
residues between positions 22 and 30.
The data shown in Figure 6 suggest that at least a considerable
portion of the U1C protein from purified HeLa Ul snRNPs is
present in dimers stabilized by a disulfide bridge. Part of the
putative U1C dimers from HeLa U1 snRNPs may have been
reduced during the preparation of the particles for which
DTT-containing buffers were used (30) which may lead to an
underrepresentation of dimers. We do not know whether the
disulfide bridges are actually present in Ul snRNP particles or that
they are formed during the snRNP isolation procedure. It is likely
that the dimers are formed by non-covalent interactions which
subsequently might facilitate the formation of a disulfide bridge.
Our data are in agreement with the estimated stoichiometry for Ul
snRNPs as proposed by Feeney et al. (33) who predicted the
presence of two U1C molecules per Ul snRNP particle.
Since the UlC homodimer might be present in Ul snRNP
particles in vivo, as suggested by the results of Figure 6, an
important question concerns the function of these U1C dimers.
Data reported by Heinrichs et al. (7) indicated that the U1C protein
is involved in the binding of the U1 snRNP particle to the
pre-mRNA 5' splice site. Possibly, stable binding to the 5' splice
site requires the presence of a U1C dimer on the Ul snRNP
particle. Within such a model it can be speculated that U1C dimers
are responsible for a direct contact with the pre-mRNA. Our
present studies are directed to test this hypothesis.
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